ELRIG Workgroups

Key objectives:

• Enhance engagement and participation of Early Career Professionals in the ELRIG network through the provision of targeted activities, opportunities and information
• Develop strategy, proposals and action plans for ECP participation. Liaise with other workgroups  and ELRIG administration team to deliver
• Track KPIs to assess performance vs objectives

Group Leader:
Mark Soave (OMass Therapeutics, Chair)

Group Members:

Lisa Stott (Nxera Pharma)
Jasmine Trigg (Sartorius)
Christopher Trevelyan (University of Leeds)
Emma Howarth (Langton Howarth)
Cassie Messenger (ELRIG Board & GSK)
Millie Fox (AstraZeneca)
Clare Viney (ELRIG Board & CRAC)
Tara Shanks (ELRIG)
Alexander Kingdon (Liverpool School of Tropical Medicine)
Alicia Overall (Domainex)
Eve Stalker (University of Cambridge)

ESWG key objectives:

• Focus will be on developing and implementing a cohesive digital content strategy, social media presence and media partnerships, improving accessibility and inclusivity, and creating additional value from its scientific content.
• It will make key recommendations that support the strategic pillars of the organization and strive to ensure that the perspectives of all its community members are considered and represented in discussion and decision.

Group Leader:
Chris Williams (ELRIG Board & Questae Consulting)

Group Members:

Sanj Kumar (ELRIG)
Emily Norman (ELRIG)
Kayvan Richter (CANCER RESEARCH HORIZONS)
Sophie Rose (METRION BIOSCIENCES)
Michelle Ricketts (CODON COMMUNICATIONS)
Alison Rawlinson (QKINE)
Abby Edwards (BIOSTRATA)
Elaine Duncan (UNIVERSITY OF GLASGOW)

Key objectives:

To assist the ELRIG Board in guiding ELRIG’s employee development, succession planning and to assess the adequacy of the Company’s human resources principles and policies.   The workgroup is also responsible for the equality, diversity and inclusion (EDI) policy, applicable to all internal and external ELRIG stakeholders and fulfilling ELRIG’s responsibilities relating to the oversight of the compensation and benefits of ELRIG employees, as well as administering the Company’s compensation.   The Committee reports to the Board of Directors

Group Leader:
Clare Viney (ELRIG Board & CRAC)

Group Members:
Paul Kendall (Watson-Marlow)
Mel Leveridge (GSK)

Key objectives:

• Assess areas of scientific interest for the ELRIG community and develop scientific conference strategy accordingly
• Build a portfolio of annual ELRIG conferences: deciding themes,  proposing format, identifying conference directors, track chairs and facilitating recruitment of appropriate speakers
• With the ELRIG office deliver impactful, high quality scientific conferences with national and international reach.

Group Leader:
Saleha Patel (ELRIG Board & AstraZeneca)

Group Members:
Roger Clark (Charles River Laboratories)
Kate Smith (GlaxoSmithKline)
Martin Main (MD Catapult)
Jon Hutchinson (GlaxoSmithKline)
Tim Hammonds (TRH Consulting)
Kathryn Chapman (VC funded BioTech Company)
Simon Chell (AstraZeneca)
Simon Ward (Cardiff University)
Thomas Lundback (AstraZeneca)
Theresia Schaedler (Maxion Therapeutics)
Alex Alderton (AstraZeneca)
Fredrik Edfeldt (AstraZeneca)

Key objectives:

• Ensure financial success of ELRIG events by engaging vendors on a broad basis and enabling effortless exchange between commercial members and the science community
• Provide attractive sponsoring options for the vendors to showcase their company and products via diverse channels
• Continuously monitor the biotech industry landscape and liaise with vendors, to guide decisions on the market potential of future events

Group Leader: Nick Clare

Group Members:
Jessica Evens (Magnitude Biosciences)
Darren Garside (High Red Bio)
Kevin  Moore (independent)
Nikki Carter (molecular Devices)
Martin Pearce (Sygnature Discovery)
Paul Wylie (Lightcast Discovery)
Miles Rackliff (Organoid Spheriod)
Karthi Rajamani (Takara Bio)
Gary Allenby (Charnwood Molecular)
Dan Thomas (Independent)
Thomas Edmonds (Independent)
Tara Shanks (ELRIG)
Sarah Lupton (ELRIG, Arveth)